Discovery of Effective Dual PROTAC Degraders with Synergistic Antitumor Activity for Overcoming Tamoxifen-Resistant Breast Cancer.

Authors

Lilan Xin, Jing Liu, Xinyi Guo, Shengnan Li, Zhangxiao Guo, Hongli Wang, Zemin Song, Xiaofei Deng, Chao Wang, Pingping Fang, Jian Huang, Chune Dong, Hai-Bing Zhou

Published in

Journal of medicinal chemistry. Jul 07, 2026. Epub Jul 07, 2026.

Abstract

Endocrine therapies for estrogen receptor-positive (ER⁺) breast cancer (BC) often encounter primary or acquired resistance, and elevated expression of histone deacetylase 6 (HDAC6) exacerbates therapeutic challenges. Emerging evidence indicates that simultaneous attenuation of estrogen receptor α (ERα) and HDAC6 activities represents a promising strategy to overcome endocrine resistance. Herein, we report a novel hybrid ERα/HDAC6 dual-targeting PROTAC V-12c, which selectively degraded ERα and HDAC6 in vitro and in vivo and exhibited superior antiproliferation efficacy across a panel of BC cell lines. Mechanistically, V-12c degraded both ERα and HDAC6 via the proteasome pathway, induced cell cycle arrest and apoptosis, attenuated hormonal response, disrupted the autophagy-lysosome function, and triggered ferroptosis, collectively contributing to overcoming tamoxifen resistance. Importantly, V-12c potently suppressed tumor growth in endocrine-resistant BC models, outperforming single-target therapies. This study identified a multimechanistic action of dual PROTAC V-12c with potent antitumor effects, providing a promising therapeutic strategy for endocrine-resistant BC.

PMID:
42411996
Bibliographic data and abstract were imported from PubMed on 07 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.